Publications database | www.emcdda.europa.eu

Displaying 1 - 20 of 1287

Joint publications

EU Drug Markets — Impact of COVID-19

What effect is COVID-19 having on the drug market in the EU? This joint publication from the EMCDDA and Europol analyses the impact of the pandemic on the market for the main drug types (cannabis, heroin, cocaine, amphetamines, NPS), including demand, production, trafficking and availability. It...

screenshot of page

Ad hoc publication

Resources on COVID-19 and drug markets

This page describes the EMCDDA's ongoing work on the impact of the COVID-19 pandemic on drug markets in the EU. As well as showcasing EMCDDA publications on the topic, it also provides the reader with useful relevant resources from partner organisations. This resource is online only and may be...

screenshot of page

Ad hoc publication

COVID-19 resource page for people who use drugs (PWUD) and drug service providers

On this page, the EMCDDA has compiled examples of advice being issued to people who use drugs and service providers by some national bodies and different associations, networks and NGOs. This resource is online only and may be accessed here >>

Technical reports

Drug-related infectious diseases in Europe: Update from the EMCDDA expert network, 2020

This 2020 EMCDDA update on drug-related infectious diseases aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020, while highlighting some of the current innovative responses to...

Ad hoc publication

EMCDDA trendspotter briefing - Impact of COVID-19 on drug services and help-seeking in Europe

Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug services in Europe, the European Monitoring Centre for...

Ad hoc publication

EMCDDA special report: COVID-19 and drugs – Drug supply via darknet markets

This report is a rapid and preliminary analysis of the impact of COVID-19 on selected online markets. Three relatively large darknet markets were reviewed for the purposes of this study, selected because of their importance to the EU market and because they could be accessed to provide information...

Timeline: EMCDDA preparedness and response

Over the past quarter of a century, the EMCDDA has expanded its monitoring capability to keep pace with revolutionary changes in the extent and nature of the drugs problem and in the world in which we live. By complementing data routinely submitted by Member States with information from an...

Initial reports

EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene)

Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and submitted to the Commission and the Member States, in...

Screenshot of poster showing key events in the area of International cooperation from the EMCDDA's first 25 years (1995-2020)

Timeline: 25 years of monitoring — selected events from the EMCDDA’s international cooperation history

Follow the timeline and take a walk through some of the key moments in the EMCDDA's 25 years of international cooperation.

publication thumbnail

Ad hoc publication

EMCDDA update on the implications of COVID-19 for people who use drugs and drug service providers

COVID-19 is a major global health threat. People who use drugs face the same risks as those of the general population and therefore need to be aware of the appropriate advice to reduce their risk of infection. They can be exposed to additional risks, however, that require developing assessment and...

Wastewater POD's cover

Perspectives on Drugs (PODs)

Wastewater analysis and drugs — a European multi-city study (Perspectives on drugs)

The findings of the largest European project to date in the emerging science of wastewater analysis are taken up in this ‘Perspective on drugs’. The project in question analysed wastewater in a range of European cities and towns to explore the drug-taking habits of those who live in them. The...

screenshot

Timeline: 25 years of monitoring — selected events from the EMCDDA’s history

Take a journey through some of the key moments in the EMCDDA’s first quarter of a century by following the timeline and checking our main milestones.

Work programmes and strategies

Programming document 2020-22

The Programming Document 2020-22 translates the long-term priorities defined by the EMCDDA Strategy 2025 into short-term operational priorities. The year 2020 marks the end of the first strategic roadmap and the beginning of the second one (towards 2025) and is a time for mid-term assessment and...

Technical reports

Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus expert network

This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of the project. The data reveal that the substances most commonly...

Technical reports

Monitoring and evaluating changes in cannabis policies: insights from the Americas

This report provides an overview of the changes in cannabis policies in the Americas and the evidence emerging from evaluations of their impact. Highlighting the challenges in monitoring and evaluating regulatory changes in the drugs field, it will be of particular interest to those involved in...

Publication cover_EWS guidelines

Manuals and guidelines

EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances

These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) with respect to information...

Technical reports

Estimating the size of the main illicit retail drug markets in Europe: an update

This report includes estimates of the total size of the retail drug market in the European Union in 2017 for cannabis, heroin, cocaine, amphetamines and MDMA. This is a supporting publication to the 2019 EU Drug Markets Report.

Online repository

Exchange prevention registry

Xchange is an online registry of evidence-based prevention interventions. It is updated approximated twice a year with new programmes and feedback from implementers. The registry makes available manualised interventions for which good European evaluation studies showed beneficial outcomes relating...

Joint publications

EU Drug Markets Report 2019

The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis presented in this report spans numerous topics such as the links between drugs and other crimes, the licit economy and society more generally as...

Drug precursor developments in the European Union

This paper describes the significant developments that have occurred in the last 5 to 10 years in the field of drug precursors related to synthetic stimulant drugs produced in the EU. This includes describing the ‘pre-precursor’ phenomenon and responses to it, both by the EU and by the drug...

1
2
3
4
5
6
7
8
9
…
next ›

.

Loading